Is Kevzara approved for polymyalgia rheumatica?
No, Kevzara (sarilumab) is not FDA-approved for polymyalgia rheumatica (PMR). It is approved for moderately to severely active rheumatoid arthritis (RA) in adults who have not responded to one or more tumor necrosis factor antagonists, either alone or with methotrexate.[1]
What is Kevzara primarily used for?
Kevzara, from Sanofi and Regeneron, targets interleukin-6 receptor (IL-6R) to reduce inflammation in RA. Clinical trials focused on RA patients, showing reduced joint damage progression when combined with methotrexate.[1][2]
Has Kevzara been studied or used off-label for PMR?
Limited case reports and small studies explore Kevzara in PMR, often for patients with relapsing disease or giant cell arteritis overlap unresponsive to steroids or tocilizumab (another IL-6 inhibitor). One case series noted symptom relief in steroid-dependent PMR patients, but no large randomized trials support routine use. Off-label application remains experimental due to lack of approval and data.[3][4]
How does PMR treatment typically work, and where does Kevzara fit?
PMR is managed first-line with low-dose glucocorticoids like prednisone, which control symptoms in most patients within days. For refractory cases, IL-6 inhibitors like tocilizumab (Actemra) have evidence from trials like GiACTA, earning approval for giant cell arteritis (PMR-related). Kevzara lacks similar PMR-specific data, so guidelines favor steroids, methotrexate, or tocilizumab over it.[5][6]
What are the risks of using Kevzara for PMR?
As an IL-6 blocker, Kevzara carries risks of serious infections, gastrointestinal perforations, and lab abnormalities like neutropenia—concerns amplified in older PMR patients (often over 50). Without PMR-specific safety data, physicians weigh these against unproven benefits.[1][2]
[1]: FDA Kevzara Label
[2]: Kevzara Prescribing Information
[3]: PubMed: Sarilumab in PMR case reports
[4]: Rheumatology Journal: Off-label IL-6 use in PMR
[5]: ACR PMR Guidelines
[6]: FDA Actemra GCA Approval